Inflammatory Bowel Diseases最新文献_第10页

Sexual Health Concerns and Health Care Experiences of LGBTQ+ Patients with Inflammatory Bowel Disease. LGBTQ+炎症性肠病患者的性健康问题及保健经验

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-21 DOI: 10.1093/ibd/izaf158

Taylor Boyd, Sonia Friedman, Kira L Newman, Victor Chedid, Heidy Judith Cabral, Rachel W Winter

{"title":"Sexual Health Concerns and Health Care Experiences of LGBTQ+ Patients with Inflammatory Bowel Disease.","authors":"Taylor Boyd, Sonia Friedman, Kira L Newman, Victor Chedid, Heidy Judith Cabral, Rachel W Winter","doi":"10.1093/ibd/izaf158","DOIUrl":"https://doi.org/10.1093/ibd/izaf158","url":null,"abstract":"Background: Sexual dysfunction is common among patients with inflammatory bowel disease (IBD). For lesbian, gay, bisexual, transgender, or queer (LGBTQ+) patients, these challenges may be compounded by health disparities related to sexual health, stigma, and fear of discrimination in the clinical setting. There has been little research related to sexual health and IBD among this patient demographic.Methods: Patients with IBD who receive care at Massachusetts General Hospital and the Brigham and Women's Hospital were invited to participate in a 4-part survey on sexual health via an electronic patient portal messaging system and outpatient clinic flyers. Patients from the broader IBD community were invited to participate via social media outlets. Demographic data, IBD disease characteristics, and information related to health care experiences and interactions with IBD providers were collected. Sexual history information was obtained using an adapted version of the IBD-Specific Sexual Dysfunction Scale.Results: In total, 340 patients completed the survey, of which 20.3% (n = 69) identified as LGBTQ+. The majority of patients (75%, n = 255) reported distress in their sexual life due to IBD; however, only 5% (n = 17) of respondents had previously discussed the topic of sexual health with their IBD provider. One in 4 LGBTQ+ patients listed fear of discrimination as a source of discomfort in these discussions, and a similar proportion expressed uncertainty regarding whether their sexual and/or gender identity negatively impacted their IBD care.Conclusions: Further research and enhanced provider awareness of sexual health challenges related to IBD among LGBTQ+ patients may serve as an important step toward advancing inclusive and culturally sensitive care for this patient population.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author's Response to Comment on "Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease". 作者对“血浆钙保护蛋白和髓过氧化物酶作为炎症性肠病的生物标志物”评论的回应。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-21 DOI: 10.1093/ibd/izaf189

Akhilesh Swaminathan, Duo Hou, Grace M Borichevsky, Anthony J Kettle, Richard B Gearry

引用次数: 0

Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN. Upadacitinib治疗儿童急性重度溃疡性结肠炎的实际经验：一项来自ESPGHAN儿科IBD Porto组的国际多中心回顾性研究。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-20 DOI: 10.1093/ibd/izaf166

Anat Yerushalmy-Feler, Elizabeth A Spencer, Suzannah Bergstein, Katarina Mitrova, Ondrej Hradsky, Matteo Bramuzzo, Magdalena Wlazlo, Christine Olbjørn, Christine Rungoe, Nathaniel Weil, Dan Turner, Shlomi Cohen

{"title":"Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN.","authors":"Anat Yerushalmy-Feler, Elizabeth A Spencer, Suzannah Bergstein, Katarina Mitrova, Ondrej Hradsky, Matteo Bramuzzo, Magdalena Wlazlo, Christine Olbjørn, Christine Rungoe, Nathaniel Weil, Dan Turner, Shlomi Cohen","doi":"10.1093/ibd/izaf166","DOIUrl":"https://doi.org/10.1093/ibd/izaf166","url":null,"abstract":"Background: Data on upadacitinib therapy for pediatric acute severe ulcerative colitis (ASC) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as a salvage therapy in pediatric ASC.Methods: Children and adolescents with ASC who were treated with upadacitinib for the induction of remission were enrolled in this retrospective multicenter study. Demographic, clinical, and laboratory data as well as adverse events (AEs) were recorded after the 8-week induction period and throughout 26 weeks of therapy. Analyses were based on the intention-to-treat principal.Results: Twenty-two patients were included (median age 15.7 [interquartile range 13.5-16.6] years, 12 hospitalized), all with anti-tumor necrosis factor (TNF) therapy refractory disease. Ten patients were treated with corticosteroids at baseline, and upadacitinib was added to an ongoing biologic therapy in five patients. At week 8 of therapy, 11 (50%) patients of the cohort remained colectomy-free and in corticosteroid-free clinical remission (CFR), and 17 (77%) patients remained colectomy-free. Normal C-reactive protein (CRP) was achieved in 9 of 11 (82%) patients who were in CFR, and fecal calprotectin <150 mcg/g in 4 of 6 (67%) patients with available data. By week 26, 14 (64%) were in CFR and 16 (73%) patients remained colectomy-free. All these patients had normal CRP levels, and 4 of 7 patients with available data had fecal calprotectin <150 mcg/g. Twelve patients reported AEs, including two serious AEs of an appendiceal neuroendocrine tumor and cytomegalovirus colitis.Conclusion: Upadacitinib is an effective induction therapy for children and adolescents with ASC after failing anti-TNF.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying Potential Targets for the Interception of Inflammatory Bowel Disease: Toward Precision Prevention. 确定炎症性肠病拦截的潜在靶点：走向精确预防。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-20 DOI: 10.1093/ibd/izaf168

Sun-Ho Lee, Emily Lopes, Jean-Frederic Colombel, Ryan Ungaro

{"title":"Identifying Potential Targets for the Interception of Inflammatory Bowel Disease: Toward Precision Prevention.","authors":"Sun-Ho Lee, Emily Lopes, Jean-Frederic Colombel, Ryan Ungaro","doi":"10.1093/ibd/izaf168","DOIUrl":"https://doi.org/10.1093/ibd/izaf168","url":null,"abstract":"There is growing recognition that inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is preceded by a prolonged preclinical phase marked by subtle but measurable changes in the immune system, gut microbiome, and epithelial barrier function. These early alterations, often detectable years before diagnosis, offer a window of opportunity for disease interception. In this review, we examine the current evidence for environmental, microbial, and molecular factors that may contribute to the initiation of IBD, with a particular focus on modifiable risk pathways. We discuss preventive strategies across different levels of risk-from lifestyle and environmental interventions in the general population to more targeted approaches in individuals with familial predisposition, such as first-degree relatives. We also highlight recent findings on emerging biomarkers, including anti-flagellin antibodies, anti-GM-CSF autoantibodies, glycome, and integrin-targeted immune responses, that could guide precision prevention efforts. While most evidence to date has focused on CD, we also review preclinical insights relevant to UC. As the field moves toward earlier identification of at-risk individuals, the concept of \"precision prevention\"-matching interventions to individual risk and biology-may ultimately shift the paradigm of IBD care from treatment to prevention.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Characteristics and Treatment Patterns in a Large Cohort of Patients with Metastatic Crohn's Disease. 转移性克罗恩病患者的临床特征和治疗模式

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-20 DOI: 10.1093/ibd/izaf164

Natalie M Baker, Karla Santiago Soltero, Joseph Ebriani, Rahul S Dalal, Alexandra P Charrow

引用次数: 0

Modified Multiplier of SES-CD: Does Complex Better the Simple? 改良的SES-CD倍率：复杂比简单好吗？

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-20 DOI: 10.1093/ibd/izaf156

Anuraag Jena, Vishal Sharma

引用次数: 0

Resolving Loss of Response to Ustekinumab in Crohn's Disease: POWER Through or Switch Treatment? 解决克罗恩病对Ustekinumab的反应丧失：POWER通过或转换治疗？

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-20 DOI: 10.1093/ibd/izaf179

Daniele Noviello, Raja Atreya, Nurulamin M Noor

引用次数: 0

Bayesian Statistics: A Narrative Review on Application in Inflammatory Bowel Diseases. 贝叶斯统计在炎症性肠病中的应用述评

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-12 DOI: 10.1093/ibd/izaf148

Houda Camara, Eric Vicaut, Bénédicte Caron, Sailish Honap, Cédric Baumann, Laurent Peyrin-Biroulet

{"title":"Bayesian Statistics: A Narrative Review on Application in Inflammatory Bowel Diseases.","authors":"Houda Camara, Eric Vicaut, Bénédicte Caron, Sailish Honap, Cédric Baumann, Laurent Peyrin-Biroulet","doi":"10.1093/ibd/izaf148","DOIUrl":"https://doi.org/10.1093/ibd/izaf148","url":null,"abstract":"Inflammatory bowel diseases (IBD) are highly heterogeneous conditions, varying in clinical manifestations, disease localization, progression, and response to treatment. Failing to account for this heterogeneity can substantially diminish the power of clinical trials and reduce the likelihood of detecting a true effect. In this review, we explore the transformative potential of Bayesian statistics in IBD clinical research, highlighting its ability to provide deeper insights, refine trial design, and facilitate more informed medical decision-making. We explain how Bayesian methods are best incorporated into innovative IBD clinical trial designs, such as single-arm trials utilizing historical data, master protocols, and adaptive trials. In adaptive designs, Bayesian techniques enable dynamic adjustments to sample sizes based on interim data, helping to maintain adequate power while optimizing resource allocation. For network meta-analysis, Bayesian statistics enhance the estimation of treatment effects in complex or sparse data situations by integrating prior knowledge and effectively managing hierarchical models. These methods are also applied in pharmacokinetic decision-making to address inter-patient variability in IBD, offering more accurate predictions of drug concentrations and target attainment at the outset of treatment. A checklist is added for non-specialist readers on how to approach reading an article that employs Bayesian methods, as part of a Users' Guide to the Literature.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis. 溃疡性结肠炎通过诱导骨髓生成加重牙周炎。

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-12 DOI: 10.1093/ibd/izaf150

Xinyi Kuang, Xiaoyue Jia, Xian Peng, Xin Zheng, Lei Zhao, Jing Xie, Liwei Zheng, Xin Xu

{"title":"Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis.","authors":"Xinyi Kuang, Xiaoyue Jia, Xian Peng, Xin Zheng, Lei Zhao, Jing Xie, Liwei Zheng, Xin Xu","doi":"10.1093/ibd/izaf150","DOIUrl":"https://doi.org/10.1093/ibd/izaf150","url":null,"abstract":"Objectives: The intercorrelations between periodontitis and inflammatory bowel disease have been recognized for years. Accumulating evidence has shown that patients with ulcerative colitis (UC) have a higher prevalence and severity of periodontitis. However, the underlying mechanisms by which UC aggravates periodontal destruction are still unclear.Methods: Multiple murine models, including DSS-induced colitis (DIC)/ligature-induced periodontitis (LIP), DIC/LIP rescued by berberine, and LIP after DIC remission models were established to investigate the mechanisms by which UC exacerbates periodontal inflammation.Results: DIC mice exhibited a disrupted intestinal barrier with dysbiotic gut microbiota, corroborating the elevated serum levels of LPS and IL-1. Compared to DIC-free/LIP mice, DIC/LIP mice showed aggravated alveolar bone resorption, with enrichment of neutrophil extracellular traps (NETs) in periodontal tissues. DIC promoted myelopoiesis of hematopoietic stem and progenitor cells (HSPCs) by up-regulating the myeloid differentiation pathway. Intragastric administration of berberine dampened DIC and rescued the myeloid skewing of HSPCs, consequently alleviating periodontal destruction. Intriguingly, LIP induction after DIC remission still exhibited aggravated periodontal destruction and myeloid skewing of HSPCs, indicating a UC-trained immunity against periodontal damage.Conclusions: Increased gut permeability and microbial dysbiosis in UC elevate the serum level of LPS and IL-1, inducing myeloid skewing of HSPCs with an immune memory. Generation of inflammatory potential myeloid cells causes NETs accumulation and aggravates periodontal destruction in the UC-related periodontitis.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. 在PUNCH CD3-OLS试验中，粪便微生物群Live-jslm （REBYOTA®）预防炎症性肠病患者复发性艰难梭菌感染的安全性和有效性

IF 4.3 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-08-01 DOI: 10.1093/ibd/izae291

Jessica R Allegretti, Paul Feuerstadt, Whitfield L Knapple, Robert Orenstein, Philippe Pinton, Alexander Sheh, Sahil Khanna

{"title":"Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.","authors":"Jessica R Allegretti, Paul Feuerstadt, Whitfield L Knapple, Robert Orenstein, Philippe Pinton, Alexander Sheh, Sahil Khanna","doi":"10.1093/ibd/izae291","DOIUrl":"10.1093/ibd/izae291","url":null,"abstract":"Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD.Methods: Participants with IBD (ulcerative colitis [UC], Crohn's disease [CD], or unspecified) who had rCDI were included. Treatment-emergent adverse event (TEAE) data were collected for up to 6 months following RBL administration. Efficacy outcomes included treatment success at 8 weeks and sustained clinical response at 6 months.Results: Overall, 793 participants were enrolled, and 697 received RBL; 74 had IBD (UC: n = 45; CD: n = 25; unspecified IBD: n = 4). TEAEs within 8 weeks of administration were reported by 45.9% and 47.5% of participants with and without IBD, respectively; most were mild or moderate gastrointestinal symptoms. Serious TEAEs within 8 weeks of administration were reported by 1.4% and 4.2% of participants with and without IBD, respectively. The treatment success rate at 8 weeks was 78.9%, and the sustained clinical response rate at 6 months was 91.1% in participants with IBD, similar to rates in participants without IBD (73.2% and 91.0%, respectively).Conclusions: The results of this subgroup analysis of PUNCH CD3-OLS suggest RBL is safe and efficacious in patients with IBD.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2112-2122"},"PeriodicalIF":4.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143038281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0